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INTRODUCTION
Tocotrienol, a compound of the vitamin E family, has recently gained considerable attention due to its potent anti-cancer activity displayed in vitro on many types of cancer, including prostate, breast, pancreatic, colorectal, lung and liver cancer [1] [2] [3] [4] . It has also been used as a therapeutic adjuvant, leading to synergistic anti-proliferative effects when associated with various anti-cancer drugs such as tamoxifen, celecoxib and gemcitabine [5] [6] [7] [8] [9] . However, its therapeutic use against cancer in vivo has been prevented by its poor bioavailability and its inability to specifically reach tumors. In order to overcome these problems, we recently entrapped the tocotrienol-rich fraction (TRF) of palm oil in tumor-targeted vesicles bearing transferrin [10] . Transferrin (Tf) is a particularly interesting ligand for active tumor targeting, as its receptors are expressed in abundance on many types of cancers [11] . Transferrinbearing vesicles provides a tumor-selective targeting strategy in addition to its passive targeting, resulting from the enhanced permeability and retention of particulate delivery systems in tumors [12] . Transferrin has been widely used as a tumor-targeting agent for tumor-targeted drug and gene delivery [11, [13] [14] [15] [16] [17] . We recently demonstrated that the intravenous injection of transferrin-conjugated vesicles entrapping TRF resulted in regression of the tumors shortly after administration of the treatment. However, this therapeutic effect was short-lived and only lasted for the duration of the treatment. We now seek to increase this therapeutic effect by optimizing the frequency of administration of the TRF vesicle formulation. The objectives of this work are therefore to assess the in vivo therapeutic efficacy of this optimized treatment. Invitrogen (Paisley, UK). All other reagents and chemicals that are not specifically mentioned below were purchased from Sigma Aldrich (Poole, UK).
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MATERIALS AND METHODS
Materials
Preparation of transferrin-bearing vesicles entrapping TRF
Transferrin-conjugated vesicles entrapping TRF were prepared and characterized as previously described [10] . To prepare control vesicles entrapping TRF, a mixture of sorbitan monostearate (Span 60; 65 mg), cholesterol (58 mg), Solulan C24 (54 mg) in 2 mL TRF solution (0.5 mg/mL, prepared in dimethylsulfoxide) was shaken at 60 o C for 1 hour, before being probe sonicated with a Soniprep 150 (MSE, United Kingdom) for 4 min. Tf-bearing vesicles were then prepared by conjugating Tf (6 mg) to the control vesicles (2 mL), using dimethylsuberimidate as a cross-linker [10] .
Unentrapped TRF, dimethylsulfoxide, free Tf and dimethylsuberimidate were removed by ultracentrifugation (150 000 g for 1h). The drug loaded vesicle pellet was then resuspended in 2 ml PBS. 
In vivo tumoricidal activity
The in vivo experiments in this study were approved by the local ethics committee and were conducted according to the UK Home Office regulations. were able to emit some light, which was detected for a constant duration of 2 min using Living Image ® software. All images were acquired using the same illumination settings.
Statistical Analysis
Results were expressed as means ± standard error of the mean (S.E.M). 
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The administration of TRF entrapped in vesicles or in solution was well tolerated by the mice and no visible signs of toxicity or significant weight loss were observed during the study (Fig.   3 ). The tumor response to treatment was more successful for B16-F10 tumors. On the last day of the experiment, 50% of B16-F10 tumors treated with Tf-bearing vesicles entrapping TRF had completely disappeared, while another 10% of tumors had regressed (Fig. 4B) . By contrast, all the other treatments resulted in 100% tumor growth.
15 As a result of this improved therapeutic effect, the survival of A431 tumors-bearing mice treated with Tf-bearing and control vesicles was extended by 23 days and 8 days respectively, in comparison with the mice receiving no treatment (Fig. 5A) . The survival was even improved on B16-F10 tumors-bearing mice, as it was respectively extended by 26 days and 3 days after treatment with Tf-bearing and control vesicles, compared to untreated mice (Fig.   5B) . However, the administration of TRF solution did not extend the survival of the animals compared to untreated mice with both tumor cell lines. have been reported with this delivery system so far [19] . In our previous studies with the Solulan-based vesicles, we demonstrated that the systemic administration of TRF entrapped in Tf-bearing vesicles were able to decrease the size of A431 tumors, but only for the duration of the treatment, which was 10 days [10] . All the tumors then grew back after halting the treatment. None of them disappeared at any time when treated with only 10 injections. By contrast, our current regimen of administration of 20 injections increased the therapeutic effect on both tested tumors, resulting in complete disappearance of 20% and 50% of them,
respectively. In addition, this therapeutic effect was maintained after halting the treatment.
The results obtained in this current study were even improved compared with those obtained with our intravenously administered Tf-conjugated, tocopheryl-based multilamellar vesicles entrapping tocotrienol, which resulted in tumor eradication of 20% of A431 tumors and 40%
of B16-F10 tumors [16] . These results demonstrate that tocotrienol is able to exert an anticancer therapeutic effect in vivo, not only as a tumor growth inhibitor or as a therapeutic adjuvant as previously described [1, 20] , provided it is targeted to the tumors. In addition, this targeted nanomedicine was able to reach subcutaneous tumor models overexpressing transferrin receptors, following intravenous injection and should therefore have the potential to reach metastatic tumors disseminated in the body.
The mechanism of action used by tocotrienol to exert its therapeutic effect in our study is still unknown. Tocotrienol has been shown to be able to activate p53, induce apoptosis and modulate Bax/Bcl-2 ratio [21] . In addition, it can inhibit angiogenesis by down regulating the expression of the vascular endothelial growth factor receptor [22] . It also exerts its anti-cancer effect by inhibiting DNA polymerase and telomerase, enzymes involved in the proliferation of cancer cells [23] [24] . The extent of the therapeutic effect observed in our study made us suggest that many of these mechanisms were involved in the anti-cancer effect observed.
There may be scope for further improvements in the in vivo activity of these nanomedicines by understanding the mechanisms behind the variability of the response between individual tumors, hopefully resulting in a further optimized therapeutic effect against tumors.
These therapeutic effects and the good tolerability of the treatments potentially make the transferrin-conjugated vesicles entrapping tocotrienol a highly promising nanomedicine, which will be further investigated.
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CONCLUSION
The entrapment of tocotrienol in transferrin-conjugated vesicles significantly increased the therapeutic efficacy of tocotrienol in vivo compared to the drug solution. The systemic injection of tocotrienol entrapped in these targeted vesicles resulted in the disappearance of 20% of A431 tumors and 50% of B16-F10 tumors on the last day of the experiment.
Consequently, the survival of the tumor-bearing mice was extended by more than 20 days compared to untreated mice, on both cancer cell lines. Transferrin-vesicles entrapping tocotrienol is therefore a highly promising therapeutic system which deserves further investigation. 
